多重化診断薬市場：方法、用途、エンドユーザー別-世界予測、2024年～2030年

多重化診断薬市場規模は2023年に149億8,000万米ドルと推計され、2024年には173億6,000万米ドルに達し、CAGR 16.62%で2030年には439億7,000万米ドルに達すると予測されます。

多重化診断薬は、1つのアッセイや検査で複数のバイオマーカーやターゲットを同時に検出・分析することができます。多重化診断薬は1つの検査に複数の検出チャンネルまたはプローブを組み込み、複数の分析物を同時に検出することができます。多重化診断薬は、複数のバイオマーカーやターゲットを考慮することで、分析対象の疾患や状態をより包括的に理解することができ、診断の精度や信頼性を高めることができます。多重化診断薬は、診断技術の向上に対する需要の高まり、がんやその他の感染症の罹患率の上昇、ゲノムや個別化医療に対する官民の支出の増加により、より一般的になってきました。しかし、多重化レベルの制限、単一検出部位間の交差感受性の可能性、多重化診断機器を扱うための訓練を受けたヘルスケア専門家の不足などが、多重化診断薬の活用を妨げています。加えて、新しく先進的な多重化診断ツールの導入や、次世代シーケンサーを用いたソリューションを生み出すための研究開発活動の重点化が、多重化診断薬市場の開拓に大きな成長機会をもたらすと期待されています。

方法診断における精度の高さから高密度多重アッセイの使用が増加

高密度多重アッセイは、その精度と感度の向上により、多くの臨床診断ラボで好まれる手法になりつつあります。低密度多重アッセイは、高密度多重アッセイに代わる経済的な方法であり、より少ない試薬とより複雑でない装置を使用するため、比較的低コストで迅速な結果を必要とするスクリーニング用途で最も一般的に使用されています。中濃度多重アッセイは、低濃度オプションと高濃度オプションのギャップを埋めるものであり、従来のアプローチよりも少ないサンプル数でより深い分析を提供します。超高濃度多重アッセイは、現在利用可能なアッセイの中で最も高度なタイプであり、ユーザーは1回の反応で複数の分析対象物を同時に分析することができます。

アプリケーションがん疾患検出における多重化診断薬の急速な普及

多重化診断薬は、正確な診断が治療計画や生活習慣の改善に役立つことから、アレルギー性疾患における重要性が高まっています。また、自己免疫疾患においても、ループスや関節リウマチなどの特定の自己免疫疾患に特徴的なバイオマーカーを同定するために使用されています。心臓病学では、心血管疾患を早期に発見し、より早期で効果的な治療介入を可能にするために、多項目診断検査が使用されています。この診断法は、臨床検体からウイルスや細菌などの感染因子を同定する上で重要です。多重化診断検査は、正常細胞と比較して腫瘍細胞における発現変化を検出する能力により、腫瘍学においてますます有用性が高まっています。

エンドユーザー：病院における多重化診断薬による高度でハイスループットなスクリーニングのニーズ

多重化診断薬のエンドユーザーは、主に医師や外科医などの医療従事者です。多重化診断薬はヒトの病気や障害を診断するために使用されます。ヘルスケア施設では、主要な疾患を診断することで、医療上の意思決定、管理、自動化、ワークフローにおいて医師を支援します。この技術は病院や臨床検査室で広く使用されており、主に高度な診断技術を駆使して、入院患者が1回の検査でスクリーニングを完了できるように支援します。特に、この技術は病気の早期発見と運用コスト削減のために臨床現場で多用されています。

地域別の洞察

米国とカナダを中心とする南北アメリカでは、高度なヘルスケアインフラ、研究開発への徹底した注力、大手診断薬企業の存在が多重化診断薬の採用を後押ししています。慢性疾患の罹患率の高さ、ヘルスケア技術への多額の投資により、これらの診断薬の使用はさらに加速しています。その結果、この地域の生産は非常に革新的であり、新しいアッセイの開発やデジタルプラットフォームの統合に重点が置かれています。APAC地域は多重化診断薬の市場が急成長しているが、その主な理由はヘルスケア支出の増加、高度な診断法に対する意識の高まり、中間層の人口増加です。中国やインドなどの国々では、現地企業が台頭し、国際的な企業が地域の製造業に投資することで、生産の現地化が進んでいます。西欧は、南北アメリカと同様に強固な基盤を持っており、確立された医療制度が多重化診断薬のような先端技術の早期導入を後押ししています。EMEAでの生産は、厳格なEU規制によって高品質が保証されています。EMEAで事業を展開する企業は、世界に事業を展開する老舗企業と、特定のニッチ市場に特化した小規模な地域企業が混在しています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは、多重化診断薬市場の評価において極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、多重化診断薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力について徹底的な評価を行います。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.多重化診断薬市場の市場規模および予測は？

2.多重化診断薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.多重化診断薬市場の技術動向と規制枠組みは？

4.多重化診断薬市場における主要ベンダーの市場シェアは？

5.多重化診断薬市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • がんやその他の感染症の蔓延
    • ゲノミクスと個別化医療への官民資金の増加
    • 自動化機器および分析システムの需要
  • 抑制要因
    • 多重化レベルが限られており、単一の検出部位間で交差感度が発生する可能性がある
  • 機会
    • 新しい高度な多重診断ツールのイントロダクション
    • 次世代シーケンシングソリューションを生み出すための研究開発活動への重点化
  • 課題
    • 多重診断機器を扱う訓練を受けたヘルスケア専門家の不足
• 市場セグメンテーション分析
  • 方法：診断における高精度のため、高密度マルチプレックスアッセイの使用が増加している
  • アプリケーション：腫瘍学疾患検出のための多重化診断薬の指数関数的使用
  • エンドユーザー：病院における多重化診断薬を使用した高度でハイスループットなスクリーニングの必要性
• 市場ディスラプション分析
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 価格分析
• 技術分析
• 特許分析
• 貿易分析
• 規制枠組みの分析

第6章 多重化診断薬市場：方法別

• 高密度マルチプレックスアッセイ
• 低密度マルチプレックスアッセイ
• 中密度マルチプレックスアッセイ
• 超高密度マルチプレックスアッセイ

第7章 多重化診断薬市場：用途別

• アレルギー疾患
• 自己免疫疾患
• 心臓病学
• 感染症
• 腫瘍学

第8章 多重化診断薬市場：エンドユーザー別

• 学術研究
• 臨床研究
• 診断ラボ
• 病院
• 製薬会社

第9章 南北アメリカの多重化診断薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋の多重化診断薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの多重化診断薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
  • ナノピンが血液ベースの結核検査を開始、HIV/結核のマルチプレックス検査の基盤を築く
  • ChromaCodeとProtean BioDiagnosticsが戦略的提携を締結し、米国でHDPCRベースのNSCLC検査を導入
  • EDPバイオテック、ニューデイ・ダイアグノスティクスとの合併を発表
  • デルタ・ダイアグノスティクス、バイオセンシング技術に革命を起こすためにシリーズA資金調達で525万ユーロ（576万米ドル）を調達
  • ChromaCode、MedGenomeとの提携を発表、インドと中東にHDPCRベースの診断を導入
  • Aptitudeは、BARDAと最大5,400万米ドルの提携契約を締結し、ポイントオブケアおよび在宅での使用に向けた診断法の開発に着手
  • Proxim Diagnostics、bioMerieuxからの戦略的投資を発表
  • 合成生物学スタートアップD-NomeがAnkur Capital、Campus Fundから150万米ドルの資金を調達
  • ALiA BioTechのワンストップ診断プラットフォームが医療の最前線にマルチプレックス検査をもたらす
  • アジレントとアコヤ・バイオサイエンス、バイオ医薬品アプリケーション向けマルチプレックス組織アッセイ開発を推進する提携を発表
• 戦略分析と提言

第13章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. MULTIPLEXED DIAGNOSTICS MARKET RESEARCH PROCESS
• FIGURE 2. MULTIPLEXED DIAGNOSTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. MULTIPLEXED DIAGNOSTICS MARKET DYNAMICS
• FIGURE 7. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. AMERICAS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 14. AMERICAS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. UNITED STATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 16. UNITED STATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 18. ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. MULTIPLEXED DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 22. MULTIPLEXED DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. MULTIPLEXED DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY HIGH DENSITY MULTIPLEXED ASSAYS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY HIGH DENSITY MULTIPLEXED ASSAYS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY LOW DENSITY MULTIPLEXED ASSAYS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY LOW DENSITY MULTIPLEXED ASSAYS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY MID-DENSITY MULTIPLEXED ASSAYS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY MID-DENSITY MULTIPLEXED ASSAYS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY VERY HIGH DENSITY MULTIPLEXED ASSAYS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY VERY HIGH DENSITY MULTIPLEXED ASSAYS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY ALLERGIC DISEASES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY ALLERGIC DISEASES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH, BY REGION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH, BY REGION, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY CLINICAL RESEARCH, BY REGION, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY CLINICAL RESEARCH, BY REGION, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 39. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY PHARMA COMPANIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 40. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY PHARMA COMPANIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 41. AMERICAS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
• TABLE 42. AMERICAS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
• TABLE 43. AMERICAS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 44. AMERICAS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 45. AMERICAS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 46. AMERICAS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 47. AMERICAS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 48. AMERICAS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 49. ARGENTINA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
• TABLE 50. ARGENTINA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
• TABLE 51. ARGENTINA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 52. ARGENTINA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 53. ARGENTINA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 54. ARGENTINA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 55. BRAZIL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
• TABLE 56. BRAZIL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
• TABLE 57. BRAZIL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 58. BRAZIL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 59. BRAZIL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 60. BRAZIL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 61. CANADA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
• TABLE 62. CANADA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
• TABLE 63. CANADA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 64. CANADA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 65. CANADA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 66. CANADA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 67. MEXICO MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
• TABLE 68. MEXICO MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
• TABLE 69. MEXICO MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 70. MEXICO MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 71. MEXICO MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 72. MEXICO MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 73. UNITED STATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
• TABLE 74. UNITED STATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
• TABLE 75. UNITED STATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 76. UNITED STATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 77. UNITED STATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 78. UNITED STATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 79. UNITED STATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 80. UNITED STATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 81. ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
• TABLE 82. ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
• TABLE 83. ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 84. ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 85. ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 86. ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 87. ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 88. ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 89. AUSTRALIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
• TABLE 90. AUSTRALIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
• TABLE 91. AUSTRALIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 92. AUSTRALIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 93. AUSTRALIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 94. AUSTRALIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 95. CHINA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
• TABLE 96. CHINA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
• TABLE 97. CHINA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 98. CHINA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 99. CHINA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 100. CHINA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 101. INDIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
• TABLE 102. INDIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
• TABLE 103. INDIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 104. INDIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 105. INDIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 106. INDIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 107. INDONESIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
• TABLE 108. INDONESIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
• TABLE 109. INDONESIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 110. INDONESIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 111. INDONESIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 112. INDONESIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 113. JAPAN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
• TABLE 114. JAPAN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
• TABLE 115. JAPAN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 116. JAPAN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 117. JAPAN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 118. JAPAN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 119. MALAYSIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
• TABLE 120. MALAYSIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
• TABLE 121. MALAYSIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 122. MALAYSIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 123. MALAYSIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 124. MALAYSIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 125. PHILIPPINES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
• TABLE 126. PHILIPPINES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
• TABLE 127. PHILIPPINES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 128. PHILIPPINES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 129. PHILIPPINES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 130. PHILIPPINES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 131. SINGAPORE MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
• TABLE 132. SINGAPORE MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
• TABLE 133. SINGAPORE MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 134. SINGAPORE MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 135. SINGAPORE MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 136. SINGAPORE MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 137. SOUTH KOREA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
• TABLE 138. SOUTH KOREA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
• TABLE 139. SOUTH KOREA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 140. SOUTH KOREA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 141. SOUTH KOREA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 142. SOUTH KOREA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 143. TAIWAN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
• TABLE 144. TAIWAN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
• TABLE 145. TAIWAN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 146. TAIWAN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 147. TAIWAN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 148. TAIWAN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 149. THAILAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
• TABLE 150. THAILAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
• TABLE 151. THAILAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 152. THAILAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 153. THAILAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 154. THAILAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 155. VIETNAM MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
• TABLE 156. VIETNAM MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
• TABLE 157. VIETNAM MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 158. VIETNAM MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 159. VIETNAM MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 160. VIETNAM MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 161. EUROPE, MIDDLE EAST & AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
• TABLE 162. EUROPE, MIDDLE EAST & AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
• TABLE 163. EUROPE, MIDDLE EAST & AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 164. EUROPE, MIDDLE EAST & AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 165. EUROPE, MIDDLE EAST & AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 166. EUROPE, MIDDLE EAST & AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 167. EUROPE, MIDDLE EAST & AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 168. EUROPE, MIDDLE EAST & AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 169. DENMARK MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
• TABLE 170. DENMARK MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
• TABLE 171. DENMARK MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 172. DENMARK MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 173. DENMARK MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 174. DENMARK MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 175. EGYPT MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
• TABLE 176. EGYPT MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
• TABLE 177. EGYPT MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 178. EGYPT MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 179. EGYPT MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 180. EGYPT MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 181. FINLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
• TABLE 182. FINLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
• TABLE 183. FINLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 184. FINLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 185. FINLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 186. FINLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 187. FRANCE MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
• TABLE 188. FRANCE MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
• TABLE 189. FRANCE MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 190. FRANCE MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 191. FRANCE MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 192. FRANCE MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 193. GERMANY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
• TABLE 194. GERMANY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
• TABLE 195. GERMANY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 196. GERMANY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 197. GERMANY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 198. GERMANY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 199. ISRAEL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
• TABLE 200. ISRAEL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
• TABLE 201. ISRAEL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 202. ISRAEL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 203. ISRAEL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 204. ISRAEL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 205. ITALY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
• TABLE 206. ITALY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
• TABLE 207. ITALY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 208. ITALY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 209. ITALY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 210. ITALY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 211. NETHERLANDS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
• TABLE 212. NETHERLANDS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
• TABLE 213. NETHERLANDS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 214. NETHERLANDS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 215. NETHERLANDS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 216. NETHERLANDS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 217. NIGERIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
• TABLE 218. NIGERIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
• TABLE 219. NIGERIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 220. NIGERIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 221. NIGERIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 222. NIGERIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 223. NORWAY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
• TABLE 224. NORWAY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
• TABLE 225. NORWAY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 226. NORWAY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 227. NORWAY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 228. NORWAY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 229. POLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
• TABLE 230. POLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
• TABLE 231. POLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 232. POLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 233. POLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 234. POLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 235. QATAR MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
• TABLE 236. QATAR MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
• TABLE 237. QATAR MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 238. QATAR MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 239. QATAR MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 240. QATAR MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 241. RUSSIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
• TABLE 242. RUSSIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
• TABLE 243. RUSSIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 244. RUSSIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 245. RUSSIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 246. RUSSIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 247. SAUDI ARABIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
• TABLE 248. SAUDI ARABIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
• TABLE 249. SAUDI ARABIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 250. SAUDI ARABIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 251. SAUDI ARABIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 252. SAUDI ARABIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 253. SOUTH AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
• TABLE 254. SOUTH AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
• TABLE 255. SOUTH AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 256. SOUTH AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 257. SOUTH AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 258. SOUTH AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 259. SPAIN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
• TABLE 260. SPAIN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
• TABLE 261. SPAIN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 262. SPAIN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 263. SPAIN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 264. SPAIN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 265. SWEDEN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
• TABLE 266. SWEDEN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
• TABLE 267. SWEDEN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 268. SWEDEN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 269. SWEDEN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 270. SWEDEN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 271. SWITZERLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
• TABLE 272. SWITZERLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
• TABLE 273. SWITZERLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 274. SWITZERLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 275. SWITZERLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 276. SWITZERLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 277. TURKEY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
• TABLE 278. TURKEY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
• TABLE 279. TURKEY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 280. TURKEY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 281. TURKEY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 282. TURKEY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 283. UNITED ARAB EMIRATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
• TABLE 284. UNITED ARAB EMIRATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
• TABLE 285. UNITED ARAB EMIRATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 286. UNITED ARAB EMIRATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 287. UNITED ARAB EMIRATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 288. UNITED ARAB EMIRATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 289. UNITED KINGDOM MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2023 (USD MILLION)
• TABLE 290. UNITED KINGDOM MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2024-2030 (USD MILLION)
• TABLE 291. UNITED KINGDOM MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 292. UNITED KINGDOM MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 293. UNITED KINGDOM MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 294. UNITED KINGDOM MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 295. MULTIPLEXED DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 296. MULTIPLEXED DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

[195 Pages Report] The Multiplexed Diagnostics Market size was estimated at USD 14.98 billion in 2023 and expected to reach USD 17.36 billion in 2024, at a CAGR 16.62% to reach USD 43.97 billion by 2030.

Multiplexed diagnostics allows simultaneous detection and analysis of multiple biomarkers or targets in a single assay or test. Multiplexed diagnostics incorporate multiple detection channels or probes within a single test, enabling the detection of multiple analytes simultaneously. Multiplexed diagnostics can provide a more comprehensive understanding of the disease or condition being analyzed by considering multiple biomarkers or targets, allowing for better accuracy and reliability in diagnostics. Multiplexed diagnostics have become more popular due to growing demand for improved diagnostic technologies, rising incidences of cancer and other infectious diseases, and greater private-public expenditure for genomes and personalized medicine. However, limited multiplexing levels, possible cross-sensitivity between single detection sites, and lack of trained healthcare professionals for handling multiplexed diagnostic equipment impede the utilization of multiplexed diagnostics. In addition, introducing new and advanced multiplexed diagnostic tools and increasing emphasis on R&D activities to generate next-generation sequencing solutions is expected to create tremendous growth opportunities for the multiplexed diagnostics market development.

Method: Increased use of high-density multiplexed assays owing to their high precision in diagnostics

High-density multiplexed assays are becoming the preferred method for many clinical diagnostic laboratories due to their increased accuracy and sensitivity. Low-density multiplexed assays are an economical alternative to high-density multiplexing, as they utilize fewer reagents and less complex instrumentation and are most commonly used in screening applications that require quick results with a relatively low cost. Mid-density multiplexed assays bridge the gap between low and high-density options, providing greater analytical depth with fewer samples than traditional approaches. Very high-density multiplexed assays are the advanced type of assay currently available, allowing users to analyze multiple analytes simultaneously in a single reaction.

Application: Exponential use of multiplexed diagnostics for oncology disease detection

Multiplexed diagnostics has become increasingly important in allergic diseases as an accurate diagnosis can help guide treatment plans and lifestyle modifications. It is also used in autoimmune disorders to identify biomarkers characteristic of particular autoimmune conditions, such as lupus or rheumatoid arthritis. Multiplied diagnostic tests are being used in cardiology to detect cardiovascular disease early, enabling earlier and more effective treatment interventions. This diagnostic is important in identifying infectious agents such as viruses or bacteria from clinical samples. Multiplexed diagnostic tests are becoming increasingly useful in oncology due to their ability to detect expression changes in tumor cells compared with normal cells.

End-User: Need for advanced and high-throughput screening with multiplexed diagnostics in hospitals

The end users of multiplexed diagnostics are predominantly healthcare professionals, such as physicians, surgeons, and other medical personnel. Multiplexed diagnostics are used to diagnose diseases and disorders in humans. In healthcare facilities, it assists doctors in medical decision-making, management, automation, and workflows by diagnosing major diseases. This technology is widely used in hospitals and clinical labs, mainly using advanced diagnostic technologies to help hospital patients complete a screening process in a single run. In particular, the technology has been heavily used in clinical settings to detect diseases early and reduce operational costs.

Regional Insights

In the Americas, particularly the United States and Canada, the adoption of multiplexed diagnostics is driven by advanced healthcare infrastructure, a rigorous focus on research and development, and the presence of major diagnostics companies. High prevalence of chronic diseases and significant investment in healthcare technology further accelerated the use of these diagnostics. Consequently, production in this region is highly innovative, with an emphasis on the development of new assays and the integration of digital platforms. The APAC region displays a rapidly growing market for multiplexed diagnostics, mainly due to increasing healthcare expenditure, rising awareness about advanced diagnostic methods, and a growing middle-class population. Countries such as China and India are witnessing increased localization of production as local companies emerge and international players invest in regional manufacturing. Western Europe has a strong foundation similar to the Americas, with well-established healthcare systems favoring early adoption of advanced technologies like multiplexed diagnostics. The production in EMEA is marked by stringent EU regulations, which ensure high-quality standards. Companies operating within EMEA are a mix of established global players and smaller regional companies focusing on specific niche markets.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Multiplexed Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Multiplexed Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Multiplexed Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AccuBioTech Co., Ltd., Agilent Technologies, Inc., Akoya Biosciences, AusDiagnostics by R-Biopharm, Baxter International Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., bioMerieux SA, Cardinal Health, Chembio, ChromaCode, Inc., Danaher Corporation, Delta Diagnostics BV, F. Hoffmann-La Roche AG, Genabio Diagnostics Inc., Hologic, Inc., Illumina, Inc., Leica Biosystems, Medtronic PLC, Merck KGaA, NanoPin Technologies, Novartis AG, PCR Biosystems, QIAGEN N.V., Quansys Biosciences Inc., Seegene, Inc., Siemens Healthineers, Thermo Fisher Scientific, Inc., and West Pharmaceutical Services.

Market Segmentation & Coverage

This research report categorizes the Multiplexed Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Method
  • High Density Multiplexed Assays
  • Low Density Multiplexed Assays
  • Mid-Density Multiplexed Assays
  • Very High Density Multiplexed Assays

• Application
  • Allergic Diseases
  • Autoimmune Diseases
  • Cardiology
  • Infectious Diseases
  • Oncology

• End-User
  • Academic Research
  • Clinical Research
  • Diagnostic Labs
  • Hospitals
  • Pharma Companies

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Multiplexed Diagnostics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Multiplexed Diagnostics Market?

3. What are the technology trends and regulatory frameworks in the Multiplexed Diagnostics Market?

4. What is the market share of the leading vendors in the Multiplexed Diagnostics Market?

5. Which modes and strategic moves are suitable for entering the Multiplexed Diagnostics Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Prevalence of cancers and other infectious diseases
    • 5.1.1.2. Rise in private-public funding for genomics & personalized medicine
    • 5.1.1.3. Demand for automated equipment & analytical systems
  • 5.1.2. Restraints
    • 5.1.2.1. Limited multiplexing levels and possible cross-sensitivity between single detection sites
  • 5.1.3. Opportunities
    • 5.1.3.1. Introduction of new and advanced multiplexed diagnostic tools
    • 5.1.3.2. Increasing emphasis on R&D activities to generate next-generation sequencing solutions
  • 5.1.4. Challenges
    • 5.1.4.1. Lack of trained healthcare professionals for handling multiplexed diagnostic equipment
• 5.2. Market Segmentation Analysis
  • 5.2.1. Method: Increased use of high-density multiplexed assays owing to their high precision in diagnostics
  • 5.2.2. Application: Exponential use of multiplexed diagnostics for oncology disease detection
  • 5.2.3. End-User: Need for advanced and high-throughput screening with multiplexed diagnostics in hospitals
• 5.3. Market Disruption Analysis
• 5.4. Porter's Five Forces Analysis
  • 5.4.1. Threat of New Entrants
  • 5.4.2. Threat of Substitutes
  • 5.4.3. Bargaining Power of Customers
  • 5.4.4. Bargaining Power of Suppliers
  • 5.4.5. Industry Rivalry
• 5.5. Value Chain & Critical Path Analysis
• 5.6. Pricing Analysis
• 5.7. Technology Analysis
• 5.8. Patent Analysis
• 5.9. Trade Analysis
• 5.10. Regulatory Framework Analysis

6. Multiplexed Diagnostics Market, by Method

• 6.1. Introduction
• 6.2. High Density Multiplexed Assays
• 6.3. Low Density Multiplexed Assays
• 6.4. Mid-Density Multiplexed Assays
• 6.5. Very High Density Multiplexed Assays

7. Multiplexed Diagnostics Market, by Application

• 7.1. Introduction
• 7.2. Allergic Diseases
• 7.3. Autoimmune Diseases
• 7.4. Cardiology
• 7.5. Infectious Diseases
• 7.6. Oncology

8. Multiplexed Diagnostics Market, by End-User

• 8.1. Introduction
• 8.2. Academic Research
• 8.3. Clinical Research
• 8.4. Diagnostic Labs
• 8.5. Hospitals
• 8.6. Pharma Companies

9. Americas Multiplexed Diagnostics Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Multiplexed Diagnostics Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Multiplexed Diagnostics Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. NanoPin Launches Blood-Based TB Test, Lays Groundwork for Multiplex HIV/TB Testing
  • 12.3.2. ChromaCode and Protean BioDiagnostics Establish Strategic Partnership to Introduce a HDPCR-based NSCLC Assay in the United States
  • 12.3.3. EDP Biotech Announces Merger with New Day Diagnostics
  • 12.3.4. Delta Diagnostics raises EUR 5.25 million (USD 5.76 million) in Series A Funding to Revolutionize Biosensing Technology
  • 12.3.5. ChromaCode Announces Partnership with MedGenome to Bring HDPCR-based Diagnostics to India and the Middle East
  • 12.3.6. Aptitude Receives up to USD 54 Million Partnership with BARDA to Develop Diagnostics for Point-of-Care and At-Home Use
  • 12.3.7. Proxim Diagnostics Announces Strategic Investment from bioMerieux
  • 12.3.8. Synthetic biology startup D-Nome raises USD 1.5 million in funding from Ankur Capital, Campus Fund
  • 12.3.9. ALiA BioTech's One-stop Diagnostic Platform Brings Multiplex Testing to the Medical Front Line
  • 12.3.10. Agilent and Akoya Biosciences Announce Partnership to Drive Multiplex Tissue Assay Development for Biopharma Applications
• 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

• 13.1. Key Company Profiles
• 13.2. Key Product Portfolio